{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"18.33","value":"6.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"To estimate the event-free survival of patients of this population. Event-free survival will be defined as the date of the first dose of study drug until failure (disease progression) or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment to be administered on an outpatient basis. All participants to be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles.","id":"OG000","title":"Experimental: PF-04449913 Treatment"}],"paramType":"MEDIAN","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"Up to 2 years, 4 months","title":"Median Event Free Survival","type":"SECONDARY","unitOfMeasure":"months"}